December 9, 2014
Adcetris (brentuximab vedotin), jointly developed by Takeda Pharmaceutical and its US partner Seattle Genetics, significantly improved progression-free survival (PFS) in patients with Hodgkin lymphoma in a placebo-controlled PIII study, the two companies said. The study dubbed AETHERA enrolled 329 Hodgkin...read more